J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on May 1, 2005

Papers In Press, published online ahead of print February 1, 2005
J. Lipid Res., doi:10.1194/jlr.M400496-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow Supplemental data
Right arrow All Versions of this Article:
M400496-JLR200v1
46/5/969    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boullier, A.
Right arrow Articles by Quehenberger, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boullier, A.
Right arrow Articles by Quehenberger, O.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on December 16, 2004
Revised on January 27, 2005
Accepted on January 31, 2005

Phosphocholine as a pattern recognition ligand for CD36

Agnes Boullier, Peter Friedman, Richard Harkewicz, Karsten Hartvigsen, Simone R Green, Felicidad Almazan, Edward A Dennis, Daniel Steinberg, Joseph L Witztum, and Oswald Quehenberger

Medicine, University of California, San Diego, La Jolla, CA 92093

Corresponding Author: oquehenberger{at}ucsd.edu

We have previously shown that CD36 recognizes oxidation products of phospholipids on oxidized LDL (OxLDL) such as 1-palmitoyl-2-(5’-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC). The current study was designed to examine whether the phosphocholine (PC) headgroup in POVPC constitutes an obligatory binding target for CD36. To examine the contribution of PC in the binding of POVPC to CD36, we used well-defined synthetic oxidized phospholipids (OxPL) crosslinked to BSA or to a hexapeptide. The OxPL-adducts were then tested for their ability to bind to CD36-transfected cells and for their ability to inhibit OxLDL binding to CD36. Both POVPC-BSA and POVPC-peptide adducts were high affinity ligands for CD36 and potent inhibitors of OxLDL binding. Enzymatic removal of the entire PC moiety of the POVPC-peptide, or of the choline headgroup alone, as well as substitution of the choline headgroup by ethanolamine abrogated the inhibitory activity of POVPC. Interestingly, PC by itself or crosslinked to BSA did not show any intrinsic competition activity. In conclusion, our data demonstrate that the PC headgroup of OxPL alone is sufficient for binding to CD36, but only if presented in the correct conformation as in OxPL of OxLDL or as in POVPC-peptide adducts.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. Harkewicz, K. Hartvigsen, F. Almazan, E. A. Dennis, J. L. Witztum, and Y. I. Miller
Cholesteryl Ester Hydroperoxides Are Biologically Active Components of Minimally Oxidized Low Density Lipoprotein
J. Biol. Chem., April 18, 2008; 283(16): 10241 - 10251.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. G. Gugiu, K. Mouillesseaux, V. Duong, T. Herzog, A. Hekimian, L. Koroniak, T. M. Vondriska, and A. D. Watson
Protein targets of oxidized phospholipids in endothelial cells
J. Lipid Res., March 1, 2008; 49(3): 510 - 520.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. E. Greenberg, X.-M. Li, B. G. Gugiu, X. Gu, J. Qin, R. G. Salomon, and S. L. Hazen
The Lipid Whisker Model of the Structure of Oxidized Cell Membranes
J. Biol. Chem., January 25, 2008; 283(4): 2385 - 2396.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W.-J. Won, M. F. Bachmann, and J. F. Kearney
CD36 Is Differentially Expressed on B Cell Subsets during Development and in Responses to Antigen
J. Immunol., January 1, 2008; 180(1): 230 - 237.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Harkewicz, E. Fahy, A. Andreyev, and E. A. Dennis
Arachidonate-derived Dihomoprostaglandin Production Observed in Endotoxin-stimulated Macrophage-like Cells
J. Biol. Chem., February 2, 2007; 282(5): 2899 - 2910.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
B. R. Mwaikambo, F. Sennlaub, H. Ong, S. Chemtob, and P. Hardy
Activation of CD36 Inhibits and Induces Regression of Inflammatory Corneal Neovascularization.
Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4356 - 4364.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. J. Binder, P. X. Shaw, M.-K. Chang, A. Boullier, K. Hartvigsen, S. Horkko, Y. I. Miller, D. A. Woelkers, M. Corr, and J. L. Witztum
Thematic review series: The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis
J. Lipid Res., July 1, 2005; 46(7): 1353 - 1363.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.